Introduction
============

In 2000, the World Health Organization estimated that more than 177 million people have diabetes. By 2025, this figure will top 300 million. Patients with type 2 diabetes have a high risk of complications such as retinopathy, nephropathy, lower extremity amputations, coronary artery disease, and cardiovascular disease (Turner et al 1988). Researchers have shown that as a result of these complications, the quality of life of patients with type 2 diabetes is remarkably lower than the quality of life of the general population ([@b21-ppa-2-21]) and also somewhat lower than patients with other chronic diseases ([@b26-ppa-2-21]). Most complications are preventable and a key strategy is metabolic control through a combination of diet, exercise, and medication. The level of hemoglobin A1c (HbA1c) has been found to be related to good diabetic control ([@b4-ppa-2-21]). However, the relationship between glycemic control and the quality of life of patients with type 2 diabetes is unclear. Some studies have shown that improved HbA1c is associated with short-term improvement in quality of life ([@b24-ppa-2-21]), while others showed no association ([@b3-ppa-2-21]; [@b1-ppa-2-21]). Directly quantifiable endpoints, such as microvascular disease, macrovascular disease, and laboratory values, are typically assessed as outcomes of good quality of care. Still, these reflect disease control rather than the patient quality of life ([@b13-ppa-2-21]). Researchers have found that physician ratings of patient health do not necessarily correspond to patient ratings ([@b18-ppa-2-21]). Patients may feel that severe dietary restriction and daily self-administration of oral medication or insulin also negatively affect their quality of life ([@b20-ppa-2-21]). Optimizing patient quality of life is a significant treatment outcome. Therefore examining how patients with type 2 diabetes understand the factors that determine their quality of life is important.

The aim of the study was to examine which factors most strongly influence the quality of life of patients with type 2 diabetes.

Methods
=======

The study was conducted in 2004--2005 in Estonia. A random sample of 40 doctors was constituted from the list of 163 family doctors of the Estonian Society of Family Doctors who had participated in our previous study ([@b22-ppa-2-21]). Twenty-seven of the selected doctors agreed to participate in this study and 21 provided patient data. Every doctor sent a coded list of their patients with type 2 diabetes. From this list, 10 randomly selected patients were allocated to this study. All patients with type 2 diabetes were considered eligible, irrespective of age, duration of diabetes, and treatment. The family doctors were asked to recruit those patients who had been selected for the study. If one patient did not agree, the next patient on the list was selected. During a visit to the family doctor, the patients signed an informed consent document, to confirm their participation in the study. The family doctors then took a blood sample from each patient to measure HbA1c, measured each patient's height, weight, and blood pressure, and listed each patient's medications for treating type 2 diabetes.

During the family doctor visit, patients completed the Rand 36-item short form health survey (SF-36), and gave the completed form to the doctor, who returned it to the investigators. The SF-36 data were scored according to the methods suggested in the SF-36 Health Survey: Manual and Interpretation Guide ([@b27-ppa-2-21]). The eight domains used to assess patient health status in this analysis were: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Role-Emotional, Social Functioning, and Mental Health. Raw scale scores were transformed to 0--100 scales, in which higher scores consistently represent better health status in all the dimensions measured.

A special questionnaire for the patients was developed by the research team, which included questions about their personal characteristics, duration of type 2 diabetes, and other potential determinants of quality of life, for example, smoking status, knowledge about the disease and its risk factors and complications, as well as information sources concerning diabetes. The questionnaire was piloted before being used in the main study, and improved according to the results gained. Patients were asked about their knowledge of risk factors and complications of diabetes. The questions were very simple and had multiple choices, for example, "Do you know which kind of complications diabetes type 2 has?" If the patient had at least 75% of the answers right, he/she was coded as being "aware" of the nature of the disease.

The study was approved by the Ethics Review Committee on Human Research of the Tartu University.

Statistics
----------

The Statistical Package for the Social Sciences (SPSS 10.0) for Windows was used in the analysis. Associations between patient characteristics and the self-reported quality of life of the patients were analyzed using nonparametric tests (Mann-Whitney U test or Kruskal-Wallis test). Nonparametric tests were used because the subscales of SF-36 were not normally distributed. Factors influencing the health of patients with type 2 diabetes were analyzed using logistic regression analysis. Factors used in the logistic regression model were 1) patient related factors: age, gender, body mass index (BMI), smoking status, awareness of disease, and 2) disease related factors: duration of diabetes, treatment regimen (diet, oral medication, or insulin), HbA1c level, and blood pressure level. Any p-values lower than 0.05 were considered significant.

Results
=======

Altogether 200 patients with type 2 diabetes were studied; 69% of them were females and 31% were males ([Table 1](#t1-ppa-2-21){ref-type="table"}). The mean age of the respondents was 64.7 years (±11.1) and the mean duration of the diabetes was 7.5 (±1.8) years. Most of the patients (70%) were receiving only oral treatment; 16% were receiving insulin treatment for diabetes ([Table 1](#t1-ppa-2-21){ref-type="table"}). Only one-fourth (24%) of the patients were classified as "being aware" of the complications and the risk factors of their disease.

Analysis showed the existence of several important links between patient characteristics and their perceived health status. The older the patient, the lower the self-reported quality of life ([Table 2](#t2-ppa-2-21){ref-type="table"}). Only the emotional well being of patients with type 2 diabetes was not influenced by age. Whether or not the patient was aware of the complications and risk factors of their disease also significantly influenced all sub-scales of quality of life. Patients with higher awareness presented a lower score of quality of life (p \< 0.001 in all cases) ([Table 2](#t2-ppa-2-21){ref-type="table"}). The sex of the patient, duration of diabetes, smoking status, and body mass index also had an important influence on most of the sub-scales of quality of life. The type of treatment received for type 2 diabetes had only a minor effect, and the level of glycosylated hemoglobin had no effect, on the quality of life of patients with type 2 diabetes ([Table 2](#t2-ppa-2-21){ref-type="table"}).

When accounting for all the variables listed in [Table 1](#t1-ppa-2-21){ref-type="table"}, logistic regression analysis showed that quality of life was most significantly affected by the extent of the patient's awareness of the complications and risk factors of diabetes, and by age, duration of disease, and BMI ([Table 3](#t3-ppa-2-21){ref-type="table"}). Patients who were not well informed had a significantly higher quality of life score. Patients' age, BMI, and duration of diabetes all lowered the quality of life score ([Table 3](#t3-ppa-2-21){ref-type="table"}).

Discussion
==========

This Estonian study aimed to establish the most significant factors that influence the quality of life of patients with type 2 diabetes. So far this is the first study on the quality of health of diabetes patients in Estonia.

Patient-perceived health status was measured using the SF-36 health survey instrument, which is approved as appropriate for examining relationships between patient experience with diabetes, quality of life and other chronic diseases, and is reliable and valid in assessing of diabetic health status ([@b9-ppa-2-21]; [@b30-ppa-2-21]). The average values of SF-36 in different domains demonstrated, as expected, lower values when compared with population averages ([@b11-ppa-2-21]).

Several studies are being and have been conducted to find out which factors influence the quality of life of patients with type 2 diabetes. The results have been contradictory, however, especially concerning the effect of the metabolic control of diabetes on quality of life ([@b29-ppa-2-21]; [@b12-ppa-2-21]), the treatment regimen ([@b27-ppa-2-21]; [@b26-ppa-2-21]; [@b20-ppa-2-21]; [@b23-ppa-2-21]), and the duration of the disease ([@b1-ppa-2-21]; [@b20-ppa-2-21]; [@b23-ppa-2-21]). Although by using univariate analysis we found that the sex of the patient, smoking status, and treatment type had some effect on the health-related quality of life, these factors were not significant after adjustment for other variables. Only the age and body mass index of the patient, as well as the duration of diabetes and whether the patient was aware of the complications and risk factors of the disease, had an independent effect on the quality of health and life. Older patients with type 2 diabetes assessed their quality of life as being significantly lower than younger patients, especially concerning physical functioning, role limitations due to physical functioning, emotional functioning, and social functioning. These findings are consistent with other studies conducted on diabetes patients ([@b5-ppa-2-21]; [@b20-ppa-2-21]) and also with studies on the general population ([@b16-ppa-2-21]). The effect of obesity in lowering the health-related quality of life of patients with type 2 diabetes, and the general population, was found to be similar in all studies ([@b20-ppa-2-21]; [@b10-ppa-2-21]; [@b8-ppa-2-21]). In our study obese patients had especially low ratings in the emotional and physical role scales. It seems that the main challenge for doctors, and patients with type 2 diabetes, is promoting regular exercise and weight loss, which are shown to improve the functional as well as emotional status of patients ([@b7-ppa-2-21]; [@b5-ppa-2-21]; [@b15-ppa-2-21]). Moreover, researchers have found that the level of self-reported exercise was the only significant self-management behavior to predict quality of life and body mass index ([@b7-ppa-2-21]; [@b15-ppa-2-21]). However, the level of exercise should be optimal, because beyond that, the effect of exercise on quality of life becomes more negative ([@b28-ppa-2-21]).

Previous studies have shown controversial results on the effect of the duration of diabetes on quality of life. Most studies have found no effect ([@b1-ppa-2-21]; [@b21-ppa-2-21]; [@b20-ppa-2-21]), but some have shown a negative effect ([@b31-ppa-2-21]; [@b23-ppa-2-21]). Our study confirms the negative effect of duration of diabetes on the energy and general health of the patient, as well as on emotional well-being and social functioning. There could be different reasons for this finding. Development of complications in the later stage of the disease, decreases quality of life. In the years of its duration, diabetes clearly has a tendency to worsen. As complications develop, new symptoms emerge and the treatment regimen tends to become more complex.

The key question is how patients manage their disease. A positive connection has been found between active, problem-oriented management behavior and an improved quality of life ([@b2-ppa-2-21]). If patients believe they are able to perform disease-specific behavior, which will be relevant to the outcome of the disease, they can positively influence health-related quality of life ([@b1-ppa-2-21]). But if the patient persists with emotion-oriented management, this may have a negative impact on psychosocial well being, causing an increased sense of burden which in turn will affect interactions with others ([@b28-ppa-2-21]). The longer patients have the illness, the worse they feel. They may lose energy, feel fatigue, and their social functioning may sharply decrease, as demonstrated in our study. Furthermore, we found that being aware of the disease and its possible complications negatively affects the patient's quality of life. Our results conflict with studies on the psychosocial aspects of diabetes, which found that those with extensive knowledge and understanding of their disease have a more positive quality of life ([@b2-ppa-2-21]; [@b28-ppa-2-21]). However, similar results to our study were demonstrated among patients with hypertension ([@b14-ppa-2-21]). Researchers found that subjects aware of having high blood pressure had a lower health-related quality of life score than subjects with high blood pressure, who were unaware of the diagnosis ([@b14-ppa-2-21]). The barriers most frequently reported by patients in previous studies were helplessness and frustration as a result of lack of glycemic control, and continued progression of the disease despite adherence ([@b17-ppa-2-21]). Therefore knowledge about the disease is not enough to guarantee improved quality of life. However, the results of a US study demonstrated that well-informed and motivated patients were more successful in obtaining and maintaining good control of their risk factors ([@b19-ppa-2-21]). The negative effect on patients' quality of life as a result of their greater awareness of the disease, might be influenced by differences in information delivery. Whilst patients can be educated toward greater autonomy, not all health professionals are ready to work in partnership with them. The study highlighted the importance of clinical staff not only gaining a better understanding of diabetes management, but also of the theoretical principles underlying patient empowerment ([@b6-ppa-2-21]).

Conclusions
===========

Our study demonstrated that the most important factors affecting the quality of life of patients with type 2 diabetes are age, duration of diabetes, BMI, and the extent of their understanding and awareness of their disease. BMI and patient awareness and understanding of disease are modifiable risk factors, but are extremely challenging issues for physicians. Family doctors should work in closer partnership with patients in order to enhance their abilities to be more autonomous in controlling their own risk factors, and learning and maintaining problem-oriented behavior.

The data referred to in the current report have been gathered with support of the Estonian Science Foundation grant No 6452. The authors report no conflict of interest.

###### 

Characteristics of respondents and distribution of SF-36 scales

  Patient characteristics (N = 200)                
  ------------------------------------------------ ---------------
  Mean (SD) age (years)                            64.7 (±11.1)
  Mean duration of type 2 diabetes (years)         7.5 (±1.8)
  Mean BMI index                                   33.0 (±6.0)
  Mean HbA1c level                                 7.5 (±6.7)
  Treatment type                                   
   Nonpharmacological                              14%
   Only oral                                       70%
   Insulin                                         16%
  Smoking status                                   
   Yes                                             16%
   No                                              84%
  Mean blood pressure level (mmHg)                 
   Systolic                                        149.3 (±18.3)
   Diastolic                                       86.2 (±11.9)
  Gender                                           
   Female                                          61%
   Male                                            39%
  Awareness of the disease and its complications   
   Yes                                             24%
   No                                              76%
  Mean (SD) SF-36 scores                           
   Physical functioning                            54.0 (±30.1)
   Role functioning/physical                       38.1 (±42.2)
   Role functioning/emotional                      41.6 (±44.8)
   Energy/fatigue                                  43.7 (±18.4)
   Emotional well being                            61.5 (±20.0)
   Social functioning                              61.3 (±28.2)
   Pain                                            53.4 (±30.9)
   General health                                  35.3 (±18.1)

**Abbreviations:** BMI, body mass index; HbA1c, hemoglobin A1c; SF-36, Rand 36-item short form health survey.

###### 

Patient and disease-related characteristics and SF-36 sub-scales (mean scores of the sub-scales and SD)

  Patient characteristics/SF-36 sub-scales   Physical function                                        Role functioning/Physical                                Role functioning/Emotional                               Energy/Fatigue                                           Emotional well being                                   Social functioning                                       Pain                                                     General health
  ------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- ------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  Age                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   \<55                                      77.8 (21.8)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   71.8 (38.0)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   73.3 (37.5)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   50.3 (16.6)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   63.5 (24.8)                                            76.9 (24.8)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   65.6 (30.5)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     42.6 (17.6)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}
   55--69                                    57.4 (28.1)                                              37.8 (41.3)                                              40.5 (44.7)                                              45.1 (18.8)                                              61.2 (27.1)                                            61.3 (27.1)                                              53.2 (30.5)                                              35.5 (17.9)
   ≥70                                       35.9 (26.3)                                              20.8 (34.6)                                              26.8 (40.6)                                              37.9 (17.6)                                              60.9 (28.3)                                            52.8 (28.3)                                              46.9 (830.5)                                             31.0 (17.7)
  Sex                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Male                                      60.8 (28.9)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   42.5 (42.6)                                              47.6 (44.7)                                              45.8 (18.6)                                              62.0 (20.3)                                            65.8 (29.4)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     56.2 (31.8)                                              37.4 (19.2)
   Female                                    49.6(30.2)                                               35.3 (35.3)                                              37.6 (44.7)                                              42.3 (18.3)                                              61.2 (19.9)                                            58.4 (27.2)                                              51.6 (30.5)                                              33.9 (17.2)
  Duration ofdiabetes (years)                                                                                                                                                                                                                                                                                                                                                                                                                             
   \<5                                       59.8 (30.5)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     42.4 (42.4)                                              44.9 (46.3)                                              46.1 (16.7)                                              64.4 (20.7)                                            65.9 (25.9)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     61.2 (29.6)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     38.2 (17.1)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}
   5--10                                     54.5 (28.3)                                              40.8 (42.9)                                              44.4 (46.1)                                              44.2 (20.4)                                              60.2 (18.1)                                            60.9 (30.9)                                              49.1 (31.9)                                              33.3 (20.8)
   \>10                                      45.9 (30.1)                                              28.3 (34.9)                                              32.5 (42.2)                                              39.5 (18.8)                                              56.7 (20.7)                                            52.5 (29.9)                                              47.6 (34.2)                                              30.9 (30.9)
  Smoking status                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Yes                                       70.8 (25.4)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   52.0 (40.8)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     63.9 (42.8)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   48.7 (16.8)                                              67.7 (19.2)                                            72.1 (25.8)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     64.1 (27.8)                                              45.5 (21.5)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}
   No                                        52.2 (30.7)                                              36.6 (42.5)                                              38.3 (45.3)                                              43.1 (18.5)                                              60.3 (20.4)                                            59.6 (28.1)                                              53.5 (32.1)                                              33.6 (17.2)
  BMI                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   \<27                                      57.0 (33.3)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     51.1 (43.6)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   50.7 (47.0)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}     47.4 (19.1)                                              66.3 (17.5)                                            64.6(22.9)                                               64.6 (23.8)                                              40.6 (19.0)
   27--33                                    59.5 (29.5)                                              43.9 (43.5)                                              47.2 (45.1)                                              45.5 (20.1)                                              62.4 (19.4)                                            64.8 (29.4)                                              54.7 (31.0)                                              35.7 (17.3)
   \>33                                      46.6 (28.6)                                              27.5 (38.1)                                              32.0 (42.7)                                              40.4 (15.7)                                              59.1 (821.1)                                           56.1 (27.8)                                              48.4 (32.1)                                              33.2 (18.5)
  Treatment type                                                                                                                                                                                                                                                                                                                                                                                                                                          
   Nonpharmacological                        48.8 (35.8)                                              36.7 (39.6)                                              29.2 (29.2)                                              42.8 (18.5)                                              59.8 (23.6)                                            63.9 (22.0)                                              48.4 (25.9)                                              33.7 (16.9)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}
   Oral                                      58.3 (30.1)                                              42.9 (44.0)                                              49.0 (47.1)                                              46.0 (17.6)                                              64.6 (18.5)                                            62.9 (29.0)                                              58.6 (32.6)                                              37.9 (18.3)
   Insulin                                   48.5 (28.8)                                              35.3 (42.2)                                              35.6 (43.6)                                              40.0 (20.9)                                              54.3 (23.5)                                            56.9 (26.6)                                              51.5 (31.8)                                              28.9 (19.5)
  HbA1c level                                                                                                                                                                                                                                                                                                                                                                                                                                             
   \<7.5                                     56.5 (30.0)                                              39.2 (41.1)                                              42.4 (45.4)                                              44.3 (17.6)                                              62.5 (20.2)                                            61.5 (29.9)                                              53.4 (31.2)                                              36.0 (17.1)
   \>7.5                                     51.5 (31.0)                                              37.5 (43.0)                                              42.3 (44.9)                                              42.8 (19.8)                                              60.7 (20.6)                                            61.6 (29.8)                                              54.8 (31.6)                                              34.3 (18.9)
  Disease awareness                                                                                                                                                                                                                                                                                                                                                                                                                                       
   Yes                                       41.9 (29.7)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   24.5 (24.5)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   28.0 (41.4)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   36.8 (41.4)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   53.8 (17.3)[\*](#tfn2-ppa-2-21){ref-type="table-fn"}   51.3 (18.9)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   38.2 (27.7)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}   25.9 (18.5)[\*\*](#tfn3-ppa-2-21){ref-type="table-fn"}
   No                                        57.8 (29.4)                                              42.5 (43.4)                                              45.9 (45.2)                                              45.9 (45.2)                                              63.9 (18.3)                                            64.5 (19.8)                                              58.2 (27.8)                                              38.2 (18.1)

**Notes:** p \< 0.05;

p \< 0.01.

**Abbreviations:** BMI, body mass index; HbA1c, hemoglobin A1c; SF-36, Rand 36-item short form health survey.

###### 

Patient characteristics and patient health (multivariate regression analysis)[\*\*](#tfn6-ppa-2-21){ref-type="table-fn"}

  Subscales of patient health/Patient characteristics   B-coefficient   p-value
  ----------------------------------------------------- --------------- ---------
  Physical functioning                                                  
   Age                                                  −0.538          \<0.000
   BMI                                                  −0.286          \<0.000
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.182           \<0.000
  Role functioning/Physical                                             
   Age                                                  −0.416          \<0.000
   BMI                                                  −0.286          \<0.000
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.195           0.008
  Role functioning/Emotional                                            
   Age                                                  −0.395          \<0.000
   BMI                                                  −0.211          0.004
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.217           0.005
  Energy/Fatigue                                                        
   Duration of diabetes                                 −0.190          0.021
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.190           0.021
  Emotional well being                                                  
   Duration of diabetes                                 −0.203          0.012
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.244           0.003
  Social functioning                                                    
   Age                                                  −0.252          0.002
   Duration of diabetes                                 −0.223          0.005
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.180           0.02
  Pain                                                                  
   Age                                                  −0.229          \<0.000
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.259           0.004
  General health                                                        
   Duration of diabetes                                 −0.185          \<0.000
   Awareness[\*](#tfn5-ppa-2-21){ref-type="table-fn"}   0.300           0.020

**Notes:** higher score, less aware;

only statistically important data are listed.

**Abbreviation:** BMI, body mass index.
